Consult your GP if you have type 2 diabetes, prediabetes, or obesity requiring personalised guidance
GLP-1 receptor agonists work by activating the GLP-1 receptors, which stimulate insulin secretion and decrease glucagon release, leading to better glycemic control
Tirzepatide, a dual GIP/GLP-1 receptor agonist, is also available in oral and sublingual compounded formats
Patients who lose little or no weight on treatment may still get a substantial cardiovascular benefit. John Deanfield, FRCP, FESC MNT spoke with Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, about this study, who commented he was pleasantly surprised by its results
PMID 11368417